Iovance Biotherapeutics, Inc. Share Price & Technical Analysis
IOVA · $4.11 (+11.08%)
Healthcare / Biotechnology
$4.11
+11.08%
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patie…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
21% return in May, -7% avg return in past 3 year May month.
49% return in 2026, 15% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -11% | 50% | -5% | -6% | 21% | – | – | – | – | – | – | – | 49% |
| 25 | -23% | -25% | -23% | 9% | -50% | 0% | 53% | -12% | 0% | -9% | 14% | 13% | -54% |
| 24 | -4% | 104% | -10% | -20% | -25% | -10% | 9% | 31% | -18% | 12% | -12% | -20% | 37% |
| 23 | 25% | -8% | -16% | -8% | 53% | -20% | 3% | -17% | -25% | -17% | 61% | 33% | 62% |
| 22 | -14% | -7% | 7% | -10% | -55% | 64% | 5% | -8% | -9% | -4% | -33% | -3% | -67% |
Monthly return % by calendar month · historical pattern, not a forecast
Bullish · Strong · Strong
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.58B
P/E ratio
—
52W high
$5.63
52W low
$1.66
Volume
2,22,37,727
Beta
0.69
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Iovance Biotherapeutics, Inc. share price today?
- Iovance Biotherapeutics, Inc. (IOVA) last traded around $4.11 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IOVA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IOVA. Download the app for real-time alerts.
- How can I analyze Iovance Biotherapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.